Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023890 (cirrhosis)
 42,195 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Although the fertility status of women with Wilson's disease may be preserved, contraceptive method choice is complicated by the tendency for some methods to have an adverse effect on hepatic function and, conversely, for liver disease to compromise the efficacy of some contraceptives. This paper presents the case of a 28-year-old woman diagnosed with Wilson's disease at 13 years of age. She presented to an Israeli hospital at 9 weeks' gestational age with bleeding esophageal varices, cirrhosis, and portal hypertension. Although the patient had been oligomenorrheic, with menses every 2-3 months, she had experienced 3 spontaneous first-trimester abortions. Due to the urgent need for a portal decompression shunt procedure and the risk of further bleeding, the patient opted to terminate the current pregnancy. To prevent conception until the patient's liver condition stabilized, she was injected with Depo-Provera and penicillamine treatment was resumed. Although IUDs and estrogen-containing oral contraceptives are relatively contraindicated in women with liver dysfunction, spermicide and barrier contraceptives are highly recommended and progesterone-only preparations can be safely prescribed.
 ...
PMID:The contraceptive choice for a Wilson's disease patient with chronic liver disease. 940 5

This article discusses the potential availability of Cyclo-Provera, a monthly injectable similar to Depo-Provera that is being considered for approval by the US Food and Drug Administration (FDA). A new drug application was filed by its marketing company, Pharmacia and Upjohn of Kalamazoo, Michigan, in September 1997. The company wants mutual recognition by the FDA in US and European markets. The Jones Institute for Reproductive Medicine at the Eastern Virginia Medical School in Norfolk recently completed a company-sponsored clinical trial of the drug. This Institute is 1 of 44 sites conducting nationwide clinical trials among a total sample of 1200 women over 5 years. Cyclo-Provera is comprised of depomedroxyprogesterone acetate (DMPA), which is the same ingredient in Depo-Provera. Cyclo-Provera has a lower dose of DMPA (25 mg) combined with 5 mg of estradiol cypionate. The ingredients are expected to provide improved monthly menstrual cycle control. Cyclo-Provera is marketed outside the US under the name Cyclofem. Cyclofem is mainly used in China and Latin America. Germany produces a similar drug. The World Health Organization (WHO) has conducted multinational studies on both drugs. WHO recommends Cyclofem for most women who desire effective, reversible contraception and who are not at risk for most cardiovascular complications. The estrogen in Cyclofem is less potent and has a shorter life span than the estrogen in combined contraceptives. WHO guidelines suggest that Cyclofem has advantages that outweigh disadvantages for smokers under 35 years old, light smokers older than 35, women with mild hypertension (160/100), women with current or medically treated gall bladder disease, or women with mild cirrhosis. Cyclofem is not recommended for heavy smokers over 35 years old, women with a history of hypertension, and women with severe cirrhosis.
 ...
PMID:New year, new option: Cyclo-Provera awaits word. 1234 12